NFE2L2 and neurodegenerative disease: A key issue for the therapeutic targeting of Nrf2 in astrocytes (e.g. via small molecules) in neurological/neurodegenerative diseases associated with oxidative stress is whether such stress has already activated Nrf2 via Keap1 inhibition, thus occluding the effect of any therapeutic intervention.